Search results
Results from the WOW.Com Content Network
Mifepristone, and also known by its developmental code name RU-486, is a drug typically used in combination with misoprostol to bring about a medical abortion during pregnancy. [8] This combination is 97% effective [ 9 ] during the first 63 days (9 weeks) of pregnancy , yet effective in the second trimester as well.
Misoprostol is most effective when it is used in combination with methotrexate or mifepristone (RU-486). [35] Mifepristone blocks signaling by progesterone , causing the uterine lining to degrade, the blood vessels of the cervix and uterus to dilate and causing uterine contraction, similar to a menstrual period , which causes the embryo to ...
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web. AOL.
In autumn 2022, Alexei Repik, [a] [b] in order to protect R-Pharm from sanctions and to allow lllumina to continue to supply materials to Moscow based Albiogen (Russian: Альбиоген), [c] transferred his share in R-Pharm to management, with Mitsui maintaining a 10% stake which it had acquired in 2017 for $200 million. [20] [21]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Language links are at the top of the page. Search. Search
RU-28362 is a synthetic androstane glucocorticoid that was developed by Roussel Uclaf. It is a selective agonist of the glucocorticoid receptor (corticoid type II receptor), but not of the mineralocorticoid receptor (corticoid type I receptor).
Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi. It was the second largest French pharmaceutical company [6] before it was acquired by Hoechst AG of Frankfurt, Germany in 1997, with pharmaceutical operations combined into the Hoechst Marion Roussel (HMR) division in the United States.